266 related articles for article (PubMed ID: 28817826)
1. Safety and Efficacy of the S-1/Temozolomide Regimen in Patients with Metastatic Neuroendocrine Tumors.
Zhao J; Zhao H; Chi Y
Neuroendocrinology; 2018; 106(4):318-323. PubMed ID: 28817826
[TBL] [Abstract][Full Text] [Related]
2. The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.
Ramirez RA; Beyer DT; Chauhan A; Boudreaux JP; Wang YZ; Woltering EA
Oncologist; 2016 Jun; 21(6):671-5. PubMed ID: 27226359
[TBL] [Abstract][Full Text] [Related]
3. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Fine RL; Gulati AP; Krantz BA; Moss RA; Schreibman S; Tsushima DA; Mowatt KB; Dinnen RD; Mao Y; Stevens PD; Schrope B; Allendorf J; Lee JA; Sherman WH; Chabot JA
Cancer Chemother Pharmacol; 2013 Mar; 71(3):663-70. PubMed ID: 23370660
[TBL] [Abstract][Full Text] [Related]
4. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
[TBL] [Abstract][Full Text] [Related]
5. Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.
Claringbold PG; Price RA; Turner JH
Cancer Biother Radiopharm; 2012 Nov; 27(9):561-9. PubMed ID: 23078020
[TBL] [Abstract][Full Text] [Related]
6. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.
Chan JA; Stuart K; Earle CC; Clark JW; Bhargava P; Miksad R; Blaszkowsky L; Enzinger PC; Meyerhardt JA; Zheng H; Fuchs CS; Kulke MH
J Clin Oncol; 2012 Aug; 30(24):2963-8. PubMed ID: 22778320
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms.
Al-Toubah T; Morse B; Strosberg J
Oncologist; 2020 Jan; 25(1):e48-e52. PubMed ID: 31455747
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine and Temozolomide as a Promising Therapy for Advanced Thymic Atypical Carcinoid.
Wang X; Li Y; Duan J; Chen Y; Yuan B; Qi Z; Tan H
Oncologist; 2019 Jun; 24(6):798-802. PubMed ID: 30413666
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors.
Squires MH; Worth PJ; Konda B; Shah MH; Dillhoff ME; Abdel-Misih S; Norton JA; Visser BC; Dua M; Pawlik TM; Schmidt CR; Poultsides G; Cloyd JM
Pancreas; 2020 Mar; 49(3):355-360. PubMed ID: 32132509
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience.
Abbasi S; Kashashna A; Albaba H
Pancreas; 2014 Nov; 43(8):1303-5. PubMed ID: 25036906
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A "Real-World" Data Analysis.
Bongiovanni A; Liverani C; Foca F; Fausti V; Di Menna G; Mercatali L; De Vita A; Riva N; Calpona S; Miserocchi G; Spadazzi C; Cocchi C; Ibrahim T
Neuroendocrinology; 2021; 111(9):895-906. PubMed ID: 33221806
[TBL] [Abstract][Full Text] [Related]
12. Safety and Feasibility of Integrating Yttrium-90 Radioembolization With Capecitabine-Temozolomide for Grade 2 Liver-Dominant Metastatic Neuroendocrine Tumors.
Soulen MC; van Houten D; Teitelbaum UR; Damjanov N; Cengel KA; Metz DC
Pancreas; 2018 Sep; 47(8):980-984. PubMed ID: 30028446
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience.
Crespo G; Jiménez-Fonseca P; Custodio A; López C; Carmona-Bayonas A; Alonso V; Navarro M; Aller J; Sevilla I; Grande E; Gajate P; Alonso-Gordoa T; Matos I; Capdevila J; Nieto B; Barriuso J
Future Oncol; 2017 Mar; 13(7):615-624. PubMed ID: 27802780
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 dose escalation trial of TAS-102 (trifluridine/tipiracil) and temozolomide in the treatment of advanced neuroendocrine tumors.
Uboha NV; Lubner SJ; LoConte NK; Mulkerin DL; Eickhoff JC; Deming DA
Invest New Drugs; 2020 Oct; 38(5):1520-1525. PubMed ID: 32253554
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms.
Al-Toubah T; Pelle E; Valone T; Haider M; Strosberg JR
J Natl Compr Canc Netw; 2021 Aug; 20(1):29-36. PubMed ID: 34433130
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.
Mitry E; Walter T; Baudin E; Kurtz JE; Ruszniewski P; Dominguez-Tinajero S; Bengrine-Lefevre L; Cadiot G; Dromain C; Farace F; Rougier P; Ducreux M
Eur J Cancer; 2014 Dec; 50(18):3107-15. PubMed ID: 25454413
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.
Kulke MH; Stuart K; Enzinger PC; Ryan DP; Clark JW; Muzikansky A; Vincitore M; Michelini A; Fuchs CS
J Clin Oncol; 2006 Jan; 24(3):401-6. PubMed ID: 16421420
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors.
Spada F; Antonuzzo L; Marconcini R; Radice D; Antonuzzo A; Ricci S; Di Costanzo F; Fontana A; Gelsomino F; Luppi G; Nobili E; Galdy S; Cella CA; Sonzogni A; Pisa E; Barberis M; Fazio N
Neuroendocrinology; 2016; 103(6):806-14. PubMed ID: 26789262
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy.
Claringbold PG; Turner JH
Neuroendocrinology; 2016; 103(5):432-9. PubMed ID: 26065489
[TBL] [Abstract][Full Text] [Related]
20. A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.
Chan JA; Blaszkowsky L; Stuart K; Zhu AX; Allen J; Wadlow R; Ryan DP; Meyerhardt J; Gonzalez M; Regan E; Zheng H; Kulke MH
Cancer; 2013 Sep; 119(17):3212-8. PubMed ID: 23733618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
